LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
TRAW
Traws Pharma, Inc.
There isn't enough reported data to score TRAW yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TRAW Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TRAW's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TRAW PE Valuation
TRAW has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TRAW Forward outlook
There aren't enough analyst estimates for TRAW to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TRAW on earnings quality, reporting a profit while its opponent remains loss making.
TRAW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.85 | +$26.27 |
| Q1 2026 | -$1.80 | +$147.96 |
| Q4 2025 | $0.82 | +$158.67 |
| Q3 2025 | -$19.65 | +$121.66 |
| Q2 2025 | -$28.12 | +$110.13 |
| Q1 2025 | -$149.76 | -$128.26 |
| Q4 2024 | -$157.85 | -$135.35 |
| Q3 2024 | -$141.31 | -$117.06 |
TRAW lost $1.85 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus down 100% for TRAW.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
TRAW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $2.7M | +4695% |
| Q1 2025 | $57K | +1.8% |
| Q4 2024 | $56K | 0% |
| Q3 2024 | $57K | 0% |
| Q2 2024 | $57K | 0% |
| Q1 2024 | $56K | 0% |
| Q4 2023 | $56K | 0% |
| Q3 2023 | $57K | 0% |
TRAW's revenue has picked up after four years of holding roughly level: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -46% | +216354 points |
| Q1 2025 | -9128% | +179 points |
| Q4 2024 | -9425% | -1457 points |
| Q3 2024 | -14975% | -6047 points |
| Q2 2024 | -216400% | -208312 points |
| Q1 2024 | -9307% | +1652 points |
| Q4 2023 | -7968% | +2271 points |
| Q3 2023 | -8928% | +968 points |
TRAW's operating margin was −46% last quarter, up 216354 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
TRAW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.6M | +$2.9M |
| Q4 2025 | -$2.8M | +$1.3M |
| Q1 2025 | -$5.4M | -$1M |
| Q4 2024 | -$4M | +$390K |
| Q1 2024 | -$4.4M | +$119K |
| Q4 2023 | -$4.4M | -$546K |
| Q2 2023 | -$4.5M | -$276K |
| Q1 2023 | -$4.5M | -$247K |
TRAW has burned cash in almost every quarter: −$18M over the past year, against −$24M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TRAW on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TRAW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +49% | +5.2M shares |
| 1 year | +120% | +8.6M shares |
| 3 years | +1797% | +15M shares |
| 5 years | +3318% | +15.4M shares |
| Available history | +96762% | +15.8M shares |
TRAW has 16M diluted shares, up 120% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TRAW Net Leverage
TRAW's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TRAW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.6 | Neutral |
| Stochastic | 5.5 | Oversold |
TRAW's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TRAW PE vs Healthcare Sector
TRAW has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TRAW on trend strength, trading above more of its moving averages.
TRAW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.39 | 28% below |
| 20 week MA | $0.50 | 44% below |
| 50 week MA | $1.19 | 76% below |
| 100 week MA | $2.12 | 87% below |
| 200 week MA | $9.74 | 97% below |
TRAW is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TRAW on returns for 2026, with the stronger performance.
TRAW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $153.8 | $176.3 | +15% |
| 2021 | $176.3 | $71.3 | -60% |
| 2022 | $71.3 | $16.5 | -77% |
| 2023 | $16.5 | $18.8 | +14% |
| 2024 | $18.8 | $13.4 | -28% |
| 2025 | $13.4 | $1.17 | -91% |
| 2026 YTD | $1.17 | $0.28 | -76% |
TRAW has finished lower in four of the last six years. It's down 76% so far in 2026.